Show simple item record

dc.contributor.authorFountzilas, Georgeen
dc.contributor.authorSkarlos, Dimosthenis V.en
dc.contributor.authorKatsohis, C.en
dc.contributor.authorPavlidis, Nicholasen
dc.contributor.authorGiannakakis, T.en
dc.contributor.authorBafaloukos, Dimitriosen
dc.contributor.authorFahantidis, E.en
dc.contributor.authorKlouvas, G. D.en
dc.contributor.authorBeer, M.en
dc.contributor.authorKosmidis, Paraskevas A.en
dc.creatorFountzilas, Georgeen
dc.creatorSkarlos, Dimosthenis V.en
dc.creatorKatsohis, C.en
dc.creatorPavlidis, Nicholasen
dc.creatorGiannakakis, T.en
dc.creatorBafaloukos, Dimitriosen
dc.creatorFahantidis, E.en
dc.creatorKlouvas, G. D.en
dc.creatorBeer, M.en
dc.creatorKosmidis, Paraskevas A.en
dc.date.accessioned2018-06-22T09:53:07Z
dc.date.available2018-06-22T09:53:07Z
dc.date.issued1995
dc.identifier.urihttps://gnosis.library.ucy.ac.cy/handle/7/41669
dc.description.abstractThe delivery of high‐dose epirubicin in patients with advanced breast cancer usually entails serious myelotoxicity and frequent treatment delays. Concurrent administration of G‐CSF probably allows the administration of epirubicin on schedule with minimal morbidity. From August 1990 to February 1992, 42 women with advanced breast cancer were treated with six cycles of epirubicin 110 mg/m2 every 4 weeks. Filgrastim 5 μg/kg per day for 14 days was administered subcutaneously starting 24 hours after chemotherapy. All patients had multiple metastatic sites, and 39 had visceral metastases. All cases were evaluable for response, toxicity, and survival. Treatment was delayed in only two cases. The actually administered average dose per unit time per patient amounted to 99.6% of the dose prescribed by the protocol. Two (4.5%; 95% confidence interval [C.I.] 0–16%) patients demonstrated a complete response and 14 (33%; 95% C.I. 19–49%) a partial response. Median time to progression was 31 weeks and median survival was 60 weeks. Severe granulocytopenia was seen in six patients; stomatitis and diarrhea in one patient each. Myoskeletal pain was noticed in 23 (55%) patients, while cardiac problems were reported in 3 cases. The present study shows that the prophylactic use of r‐met‐hu G‐CSF allows the administration of high‐dose epirubicin every 4 weeks with minimal morbidity and an improved quality of life. © 1995 Wiley‐Liss, Inc. Copyright © 1995 Wiley‐Liss, Inc., A Wiley Companyen
dc.language.isoengen
dc.sourceMedical and pediatric oncologyen
dc.subjectArticleen
dc.subjectHumanen
dc.subjectAgeden
dc.subjectAdulten
dc.subjectBreast canceren
dc.subjectBreast neoplasmsen
dc.subjectFemaleen
dc.subjectMajor clinical studyen
dc.subjectAdvanced canceren
dc.subjectCancer survivalen
dc.subjectPriority journalen
dc.subjectAlopeciaen
dc.subjectAntineoplastic combined chemotherapy protocolsen
dc.subjectClinical trialen
dc.subjectDiarrheaen
dc.subjectGranulocyte colony-stimulating factoren
dc.subjectMulticenter studyen
dc.subjectRecombinant granulocyte colony stimulating factoren
dc.subjectStomatitisen
dc.subjectCardiotoxicityen
dc.subjectDrug administration scheduleen
dc.subjectDose responseen
dc.subjectEpirubicinen
dc.subjectGranulocytopeniaen
dc.subjectSubcutaneous drug administrationen
dc.subjectBlood toxicityen
dc.subjectNauseaen
dc.subjectBone marrow toxicityen
dc.subjectDrug megadoseen
dc.subjectQuality of lifeen
dc.subjectMiddle ageen
dc.subjectFilgrastimen
dc.subjectGrowth factoren
dc.subjectRecombinant proteinsen
dc.subjectLeukopeniaen
dc.titleHigh‐dose epirubicin and r‐met‐hu G‐CSF (Filgrastim) in the treatment of patients with advanced breast cancer: A hellenic cooperative oncology group studyen
dc.typeinfo:eu-repo/semantics/article
dc.identifier.doi10.1002/mpo.2950240106
dc.description.volume24
dc.description.issue1
dc.description.startingpage23
dc.description.endingpage28
dc.author.facultyΙατρική Σχολή / Medical School
dc.author.departmentΙατρική Σχολή / Medical School
dc.type.uhtypeArticleen
dc.contributor.orcidPavlidis, Nicholas [0000-0002-2195-9961]
dc.gnosis.orcid0000-0002-2195-9961


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record